Irbesartan
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Irbesartan |
| DrugBank ID | DB01029 |
| Brand Names (EU) | Irbesartan Teva |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.31% |
Approved Indication (EMA)
Treatment of essential hypertension. Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | malignant hypertensive renal disease | 99.31% | DL |
| 2 | malignant renovascular hypertension | 99.31% | DL |
| 3 | pulmonary hypertension with unclear multifactorial mechanism | 99.25% | DL |
| 4 | pulmonary hypertension owing to lung disease and/or hypoxia | 99.25% | DL |
| 5 | Braddock syndrome | 98.99% | DL |
| 6 | hypertensive disorder | 98.97% | DL |
| 7 | Prinzmetal angina | 98.87% | DL |
| 8 | autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndrome | 98.72% | DL |
| 9 | brain small vessel disease 1 with or without ocular anomalies | 98.66% | DL |
| 10 | diabetic nephropathy | 97.09% | DL |
| 11 | chronic pulmonary heart disease | 96.53% | DL |
| 12 | obsolete susceptibility to ischemic stroke | 95.70% | DL |
| 13 | brain stem infarction | 95.05% | DL |
| 14 | intracerebral hemorrhage | 94.63% | DL |
| 15 | cerebral infarction | 93.73% | DL |
| 16 | cerebral arterial disease | 90.39% | DL |
| 17 | cerebral artery occlusion | 89.83% | DL |
| 18 | MRI defined brain infarct | 86.14% | DL |
| 19 | ABri amyloidosis | 82.94% | DL |
| 20 | cerebrovascular disorder | 82.24% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.